- Home
- EAD vs LXEO Comparison
EAD vs LXEO Comparison
Compare EAD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EAD | LXEO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.0M | 396.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | EAD | LXEO |
|---|---|---|
| Price | $6.41 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 233.2K | ★ 855.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.24 | $3.99 |
| 52 Week High | $7.15 | $10.99 |
Technical Indicators
Market Signals| Indicator | EAD | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 49.75 |
| Support Level | $6.37 | $4.39 |
| Resistance Level | $6.45 | $5.38 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 75.00 | 29.27 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. The Fund seeks a high level of current income. Capital appreciation is a secondary objective. The fund has single operating segment.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.